Machine signal
Active cluster sell — 4 distinct insiders, $17.8M, window ends Sep 11, 2026.
Figures computed from official regulatory filings — .
Analysttarget 103.17 USD (+60%) · consensus 4.92/5 · 13 buy · 0 hold · 0 sell
Ownershipinsiders 7.84% · institutions 114.12% · short 21.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Disc Medicine, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
21 buys357 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Quisel John D | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Quisel John D | Exercise | $36.4K | SEC |
| Bitterman Kevin | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bitterman Kevin | Sell | $1.9M | SEC |
| Bitterman Kevin | Exercise | $508.6K | SEC |
| Bitterman Kevin | Exercise | $326K | SEC |
| Bitterman Kevin | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bitterman Kevin | Exercise | $388.5K | SEC |
| Bitterman Kevin | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bitterman Kevin | Sell | $72.9K | SEC |
| Bitterman Kevin | Sell | $60.7K | SEC |
| Bitterman Kevin | Sell | $1.4K | SEC |
| Bitterman Kevin | Sell | $4.3K | SEC |
| Bitterman Kevin | Sell | $162 | SEC |
| Bitterman Kevin | Sell | $5.6K | SEC |
| Bitterman Kevin | Sell | $224.7K | SEC |
| Bitterman Kevin | Sell | $1.8M | SEC |
| Bitterman Kevin | Sell | $41K | SEC |
| Bitterman Kevin | Sell | $80 | SEC |
| Bitterman Kevin | Sell | $187.1K | SEC |
| Bitterman Kevin | Sell | $728.8 | SEC |
| Bitterman Kevin | Sell | $809.8 | SEC |
| Bitterman Kevin | Sell | $2.1M | SEC |
| Bitterman Kevin | Sell | $4.6K | SEC |
| Yu Jonathan Yen-Wen | Sell | $24.8K | SEC |